Custom service
Phospho Antibody Production
Specific for the modified residue, blind to the unmodified protein.
A phospho-specific antibody has one job and one failure mode. The job is to bind a peptide carrying a phosphate on a defined residue; the failure is to bind the same peptide without it. Because the unmodified form is usually far more abundant in a cell lysate, even a small preference for the unphosphorylated sequence becomes the dominant signal.
The immunogen is a short phosphopeptide, 8–15 residues, synthesised with the phosphate already installed on the target serine, threonine or tyrosine. A cysteine is added at the N- or C-terminus for maleimide coupling to KLH, which keeps the modified residue central and exposed. Phosphopeptide synthesis is not trivial — the phosphate must survive coupling, injection and processing — and the coupling ratio and phosphate retention are confirmed by MALDI-TOF before immunisation.
Screening is differential by design. Each supernatant is tested against the phosphopeptide and the identical unphosphorylated peptide, and only clones with a phospho-to-unphospho ratio above ten are carried forward. The second screen is biological: the antibody must detect the target in cells treated with a phosphatase inhibitor and lose that signal after lambda phosphatase treatment, which is the only evidence that it recognises the modification rather than the sequence.
Service Highlights
Where it fits
Phospho-specific antibodies are the workhorse of signalling research: receptor tyrosine kinase activation, MAPK and PI3K pathway readouts, checkpoint phosphorylation and kinase inhibitor pharmacodynamics. They are equally important as IHC reagents for quantifying pathway activation in fixed tissue.
They are unreliable for sites that sit in a highly conserved sequence shared across protein families, or where the modification is present on only a small fraction of the protein. In those cases a recombinant binder selected by phage display, or a mass-spectrometry-based readout, may be the more honest route.
Documentation and QC
Every clone ships with a phospho/unphospho ELISA ratio, a Western blot on stimulated and unstimulated lysates, and phosphatase-treated controls. Cross-reactivity against the unmodified protein at high loading is documented, because that is the condition under which these reagents most often fail.
Frequently asked questions
What phospho/unphospho ratio should we expect?
A ratio of ten or higher in ELISA usually translates into usable discrimination on a membrane. Ratios between three and ten often look acceptable in ELISA and fail in a lysate, which is why we report the number rather than a pass or fail.
Can you target a site with no commercial antibody available?
Yes, that is the usual reason for the project. What we need is the site, the protein accession, and ideally a cell system in which the modification is known to occur.
Do you validate in IHC?
On request. Antigen retrieval, fixation and phosphatase treatment all affect phospho-epitope detection, and IHC validation is scoped as a separate work package because it can require a different clone.
Send the site and the stimulus that induces it. If the modification is not detectable in any available cell system, no antibody will make it detectable, and we will say so at the start.
Service Highlights
- Paired peptide screening. Phosphorylated and unphosphorylated versions of the same sequence, synthesised and purified in parallel, tested side by side on every plate.
- Ratio-based selection. Positives are ranked by phospho/unphospho ratio, not by absolute signal, because absolute signal selects for abundance rather than specificity.
- Phosphatase validation. Lysates treated with lambda or calf intestinal phosphatase are compared with untreated lysates by Western blot.
- Residue context preserved. +3 and −3 positions from the native sequence are retained, since kinases and antibodies both read the flanking residues.
- Multiple modification types. Phospho, acetyl, methyl, ubiquitin and SUMO peptide immunogens using the same workflow.
- Application testing. Western blot, IHC and flow on stimulated versus unstimulated cells, reported as performed.
How the work runs
Site selection
The target residue, its flanking sequence and the known stimulus are reviewed. Sites within highly conserved regions or with many homologues are flagged, because cross-reactivity is more likely there.
Phosphopeptide synthesis
Fmoc SPPS with phospho-amino acid building blocks, HPLC to >90%, identity by ESI-MS, and phosphate retention confirmed after conjugation.
Immunisation
100–200 µg conjugate per injection, four to five times. Two carriers are alternated to reduce carrier dominance.
Differential ELISA
Every well is tested on phospho and unphospho peptide plates; the ratio and the absolute signal are both recorded, and only high-ratio wells are expanded.
Biological validation
Western blot on treated and untreated cell lysates, with phosphatase-treated controls and, where available, site-mutant lysates.
Subcloning and application testing
Two rounds of cloning, isotyping, then testing in the intended application — IHC on FFPE tissue often requires a different clone than Western blot.
Specifications & timeline
- Targets
- pSer, pThr, pTyr — plus acetyl, methyl, ubiquitin
- Specificity
- >10× ratio — phospho vs unphosphorylated
- Timeline
- 12–16 weeks — with negative screening
- Peptide length
- 8–15 residues, with native flanking sequence
- Modifications
- Phospho-Ser/Thr/Tyr, acetyl-Lys, methyl-Lys/Arg, K48/K63 ubiquitin chains
- Screening
- Differential ELISA, phospho/unphospho ratio ≥10 required
- Validation
- Lambda phosphatase treatment, site mutants, stimulated versus resting cells
- Timeline
- 12–16 weeks for synthesis, immunisation, screening and cloning
- Deliverables
- 2–5 clones or 5–20 mg polyclonal, ELISA ratio data, Western blot validation images
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.